Construction of Salmonella typhimurium YG7108 strains, each coexpressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase

Environmental and Molecular Mutagenesis

Volumn 38, Issue 4, 2001, Pages 329-338

  Fujita, Ken Ichi ^a   Nakayama, Kazuo ^a   Yamazaki, Yoshiyuki ^a   Tsuruma, Kazuhiro ^a   Yamada, Masami ^b   Nohmi, Takehiko ^b   Kamataki, Tetsuya ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

Enzyme activity; Heterologous expression; Kinetic parameter

Indexed keywords

ALKYLATING AGENT; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 ISOENZYME; DNA METHYLTRANSFERASE; METHYLGUANIDINE; PROMUTAGEN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME KINETICS; GENETIC ENGINEERING; HUMAN; LIVER MICROSOME; MUTAGENICITY; NONHUMAN; PROTEIN EXPRESSION; SALMONELLA TYPHIMURIUM; STRAIN DIFFERENCE;

ALKYLATING AGENTS; ARYL HYDROCARBON HYDROXYLASES; COUMARINS; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DICLOFENAC; ETHANOLAMINES; GENETIC ENGINEERING; HUMANS; MIDAZOLAM; MIXED FUNCTION OXYGENASES; MUTAGENICITY TESTS; NADP; NADPH-FERRIHEMOPROTEIN REDUCTASE; NITROSAMINES; RECOMBINANT PROTEINS; SALMONELLA TYPHIMURIUM; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES;

ADA; SALMONELLA TYPHIMURIUM;

EID: 0035681393     PISSN: 08936692     EISSN: None     Source Type: Journal    
DOI: 10.1002/em.10034     Document Type: Article

References (69)

1. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine
2. Relevance of nitrosamines to human cancer
3. + for all three chromosomally located systems of DNA restriction and modification
4. Human cytochrome P450IIA3: cDNA sequence, role of the enzyme in the metabolic activation of promutagens, comparison to nitrosamine activation by human cytochrome P450IIE1
5. Human cell lines, derived from AHH-1 TK+/- human lymphoblasts, genetically engineered for expression of cytochromes P450
6. Development of a human lymphoblastoid cell line constitutively expressing human CYP1B1 cDNA: Substrate specificity with model substrates and promutagens
7. Taxol metabolism by human liver microsomes: Identification of cytochrome P450 isozymes involved in its biotransformation
8. Stereo- and regioselectivity of hepatic oxidation in man-effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation
9. Somatic mutation theory of carcinogenesis
10. Expression of cytochrome P450 3A5 in Escherichia coli: Effects of 5′ modification, purification, spectral characterization, reconstitution conditions, and catalytic activities
11. Evidence that CYP2C-19 is the major (S)-mephenytoin 4′-hydroxylase in humans
12. Human P450PCN1: Sequence, chromosome localization, and direct evidence through cDNA expression that P450PCNI is nifedipine oxidase
13. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily
14. An improved assay of 7-ethoxycoumarin-deethylase activity: Induction of hepatic enzyme activity in C57BL/6J and DBA/2J mice by phenobarbital, 3-methylcholanthrene and 2,3,7,8-tetrachlorodibenzo-p-dioxin
15. Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy
16. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes
17. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism
18. Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke
19. Nicotine-derived N-nitrosamines and tobacco-related cancer: Current status and future directions
20. Human CYP1A2: Sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression
21. Evidence for biochemically different types of vesicles in the hepatic microsomal fraction
22. High catalytic activity of human cytochrome P450 co-expressed with human NADPH-cytochrome P450 reductase in Escherichia coli
23. Human P-450 gene sequence and correlation of mRNA with genetic differences in benzo[a]pyrene metabolism
24. Flavodoxin and NADPH-flavodoxin reductase from Escherichia coli support bovine cytochrome P450c17 hydroxylase activities
25. N-Hydroxylation of carcinogenic and mutagenic aromatic amines
26. The human debrisoquine 4-hydroxylase (CYP2D) locus: Sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene
27. Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs
28. Isolation of a new human fetal liver cytochrome P450 cDNA clone: Evidence for expression of a limited number of forms of cytochrome P450 in human fetal livers
29. Fetus-specific expression of a form of cytochrome P450 in human liver
30. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4
31. Mephenytoin hydroxylation deficiency: Kinetics after repeated doses
32. Development of a Salmonella tester strain sensitive to promutagenic N-nitrosamines: Expression of recombinant CYP2A6 and human NADPH-cytochrome P450 reductase in S. typhimurium YG7108
33. Metabolic activation of N-alkylnitrosamines in genetically engineered Salmonella typhimurium expressing CYP2E1 or CYP2A6 together with human NADPH-cytochrome P450 reductase
34. Preparation and characterization of microsomal fractions for studies on xenobiotic metabolism
35. Purification and characterization of human liver cytochrome P-450-ALC
36. TB (CYP2C): A major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver
37. Perinatal expression and inducibility of human CYP3A7 in C57BL/6N transgenic mice
38. Revised methods for the Salmonella mutagenicity test
39. Mephenytoin hydroxylation polymorphism: Characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo
40. Role of N-nitroso compounds (NOC) and N-nitrosation in etiology of gastric esophageal, nasopharyngeal and bladder cancer and contribution to cancer of known exposures to NOC
41. 1 antagonist promethazine in human liver microsomes
42. P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature
43. Six-base deletion occurring in messages of human cytochrome P-450 in the CYP2C subfamily results in reduction of tolbutamide hydroxylase activity
44. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature
45. Specificity of substrate and inhibitor probes for cytochrome P450s: Evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes
46. Biotransformation of xenobiotics
47. Species differences and inter-individual variation in liver microsomal cytochrome P450 2A enzymes: Effects on coumarin, dicumarol, and testosterone oxidation
48. Temperature dependence of cytochrome P-450 reduction
49. Hepatic triphosphopyridine nucleotide (TPN)-cytochrome c reductase: Isolation, characterization and kinetic studies
50. Chemical carcinogenesis
51. Selective biotransformation of taxol to 6α-hydroxytaxol by human cytochrome P450 2C8
52. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily
53. Expression of modified cytochrome P450 2C10 (2C9) in Escherichia coli, purification, and reconstitution of catalytic activity
54. Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Purification and characterization of two similar forms involved in the reaction
55. Characterization of human lung microsomal cytochrome P-450 IA1 and its role in the oxidation of chemical carcinogens
56. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
57. Recombinant human cytochrome P450 1B1 expression in Escherichia coli
58. Prediction of human liver microsomal oxidation of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes
59. CYP2C9 Ile359 and Leu359 variants: Enzyme kinetic study with seven substrates
60. Isolation and characterization of the human cytochrome P450 CYP1B1 gene
61. Interaction between NADPH-cytochrome P-450 reductase and cytochrome P-450 in the membrane of phosphatidylcholine vesicles
62. Human ethanol-inducible P450IIE1: Complete gene sequence, promoter characterization, chromosome mapping, and cDNA-directed expression
63. Role of metabolism in chemical toxicity
64. Purification and characterization of ethanol-inducible human hepatic Cytochrome P-450HLj
65. Smoking and lung cancer: Scientific challenges and opportunities
66. 6-methylguanine
67. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes
68. Expression of a human P-450IIC gene in yeast cells using galactose-inducible expression system
69. Purification and characterization of human liver microsomal cytochrome P-450 2A6